shutterstock-239918923
Shutterstock/Early Spring
30 April 2015BiotechnologyHazel Ford and Leythem Wall

A trump card for challengers

As we bear witness to the rising popularity of the new post-grant proceedings in the US, we can reflect upon the long-standing procedures for pre-grant observations and post-grant oppositions at the European Patent Office (EPO).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
26 June 2026   Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.
Biotechnology
25 June 2026   Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.
Biotechnology
22 June 2026   The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.